RxDoctor Payments Data

Betty Hinderks Davis, MD

MOHS-Micrographic Surgery · Surprise, AZNPI 1417906280

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 64 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AbbVie at 43.8% of the total. That places this record below the midpoint for mohs-micrographic surgery clinicians in AZ, where the typical reported total is $1,522.

$1,522in general payments, 2019–2025

Across 64 payments — averaging $23.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$667
  • Sanofi$452
  • Regeneron Healthcare Solutions, Inc.$112
  • Amgen$75
  • LEO Pharma Inc.$35
  • UCB, Inc.$35
  • plus $146 from 6 others

What the payments were for

  • Food & beverage$1,522100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,522 in reported general payments places this provider in the 50th percentile of 38 mohs-micrographic surgery providers in Arizona.

See all mohs-micrographic surgery providers in Arizona

Medicare billing

Part B allowed, 2024
$1,845,711
Medicare patients
2,924
Services billed
19,465

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast22$115,267
Triamcinolone Acetonide246$3,739
Clobetasol Propionate75$3,262
Metronidazole62$2,634
Fluorouracil51$2,615
Doxycycline Hyclate153$2,038
Clindamycin Phosphate28$1,120
Ketoconazole56$1,082
ValacyclovirValacyclovir Hcl27$1,003
Mupirocin121$989
Finasteride64$752
Minoxidil37$442
Doxycycline Monohydrate18$416
Fluocinolone AcetonideFluocinolone/Shower Cap11$353
Amoxicillin322$349

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$75$115,26722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 38 mohs-micrographic surgery providers in Arizona.

Other mohs-micrographic surgery in Surprise

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →